貨號:A136097
同義名:
NSC-187208; CHQ
Chloroquine 是一種抗瘧藥物,同時也是自噬抑制劑,對自噬過程具有抑制作用,IC50 值為 2.1 μM。Chloroquine 具有抗瘧、抗炎和抗腫瘤作用,可用于自噬研究和抗瘧疾治療。


| 規格 | 價格 | 會員價 | 庫存 | 數量 | ||||
|---|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} {[ size_append(item.pr_size_append, item.pr_am, item.pr_size) ]} | 咨詢 | 咨詢 |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 現貨 1周 咨詢 | - + |
快速發貨 順豐冷鏈運輸,1-2 天到達
品質保證
技術支持
免費溶解

| 產品名稱 | HIV Protease ↓ ↑ | HIV-1 caspid ↓ ↑ | 其他靶點 | 純度 | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dextran sulfate sodium salt(MW 40000) | ? | M.W 40000 | |||||||||||||||||
| Vicriviroc maleate | ? | 98% | |||||||||||||||||
| Rosamultin | ? | 97% | |||||||||||||||||
| Darunavir | ? | 98% | |||||||||||||||||
| Lopinavir |
++++
HIV protease, Ki: 1.3 pM |
99+% | |||||||||||||||||
| Chloroquine | ? | Autophagy | 95% | ||||||||||||||||
| Amprenavir |
+
HIV protease, IC50: 14.6 ng/mL |
PXR | 99%+ | ||||||||||||||||
| NBD-556 | ? | 99%+ | |||||||||||||||||
| Nelfinavir Mesylate |
+++
HIV protease, Ki: 2 nM |
99%+ | |||||||||||||||||
| Atazanavir Sulfate | ? | 98% | |||||||||||||||||
| Limonin | ? | 98% | |||||||||||||||||
| Saquinavir |
++
HIV proteinase, IC50: 2.7 nM |
98% | |||||||||||||||||
| Ritonavir | ? | 98% | |||||||||||||||||
| Azvudine | ? | 98% | |||||||||||||||||
| Lenacapavir |
++++
HIV-1 capsid, EC50: 0.1 nM |
97% | |||||||||||||||||
| 1. 鼠標懸停在“+”上可以顯示相關IC50的具體數值。"+"越多,抑制作用越強。2. "?"表示該化合物對相應的亞型有抑制作用,但抑制強度暫時沒有相關數據。 | |||||||||||||||||||
| 產品名稱 | ATM ↓ ↑ | ATR ↓ ↑ | 其他靶點 | 純度 | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Wortmannin |
++
ATM, IC50: 150 nM |
MLCK,PI3K,DNA-PK | 99%+ | ||||||||||||||||
| CP-466722 |
+
ATM, IC50: 410 nM |
99%+ | |||||||||||||||||
| Torin 2 |
++
ATM, EC50: 28 nM |
++
ATR, EC50: 35 nM |
mTOR,DNA-PK | 99%+ | |||||||||||||||
| KU-55933 |
+++
ATM, IC50: 12.9 nM |
96% | |||||||||||||||||
| ETP-46464 |
+
ATM, IC50: 545 nM |
+++
ATR, IC50: 14 nM |
mTOR,DNA-PK | 98% | |||||||||||||||
| CGK733 |
++
ATM, IC50: 200 nM |
++
ATR, IC50: 200 nM |
99%+ | ||||||||||||||||
| AZD0156 | ? | 99%+ | |||||||||||||||||
| Dactolisib |
+++
ATR, IC50: 21 nM |
98+% | |||||||||||||||||
| Ceralasertib |
++++
ATR, IC50: 1 nM |
99%+ | |||||||||||||||||
| Berzosertib |
+++
ATR, IC50: 19 nM |
99%+ | |||||||||||||||||
| VE-821 |
+++
ATR, Ki: 13 nM |
99%+ | |||||||||||||||||
| AZ20 |
++++
ATR, IC50: 5 nM |
mTOR | 99%+ | ||||||||||||||||
| Schizandrin B |
+
ATR, IC50: 7.25 μM |
P-gp | 98% | ||||||||||||||||
| m-PEG25-NHS ester |
++++
ATR, IC50: 7 nM |
95% | |||||||||||||||||
| 1. 鼠標懸停在“+”上可以顯示相關IC50的具體數值。"+"越多,抑制作用越強。2. "?"表示該化合物對相應的亞型有抑制作用,但抑制強度暫時沒有相關數據。 | |||||||||||||||||||
| 產品名稱 | Autophagy ↓ ↑ | 其他靶點 | 純度 | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SBI-0206965 |
+++
ULK1, IC50: 108 nM ULK2, IC50: 711 nM |
95% | |||||||||||||||||
| Hydroxychloroquine sulfate | ? | 99% | |||||||||||||||||
| Valproic acid sodium | ? | HDAC | 97% | ||||||||||||||||
| PFK-015 |
++
PFKFB3, IC50: 207 nM |
99%+ | |||||||||||||||||
| MRT68921 HCl |
++++
ULK1, IC50: 2.9 nM ULK2, IC50: 1.1 nM |
99%+ | |||||||||||||||||
| ROC-325 | ? | 99%+ | |||||||||||||||||
| Autophinib |
+++
Autophagy, IC50: 40 nM |
99% | |||||||||||||||||
| Lys05 | ? | 99%+ | |||||||||||||||||
| 1. 鼠標懸停在“+”上可以顯示相關IC50的具體數值。"+"越多,抑制作用越強。2. "?"表示該化合物對相應的亞型有抑制作用,但抑制強度暫時沒有相關數據。 | |||||||||||||||||||
| 靶點 |
|
| 描述 | Chloroquine is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine (CHQ, 20 μM) inhibits IL-12p70 release and reduces Th1-priming capacity of activated human monocyte-derived Langerhans-like cells (MoLC). Chloroquine (20 μM) enhances IL-1–induced IL-23 secretion in MoLC and subsequently increases IL-17A release by primed CD4+ T cells[1]. Chloroquine suppressed matrix metalloproteinase (MMP)-2 and MMP-9 mRNA expression and protein activity, whereas MMP-13 mRNA expression and proteolytic activity were increased. Despite enhancing TLR9 mRNA expression, chloroquine suppressed TLR9 protein expression in vitro. Daily treatment of mice with intraperitoneal (i.p.) chloroquine (80 mg/kg/day) for 22 days, did not inhibit the growth of control siRNA or TLR9 siRNA MDA-MB-231 breast cancer cells[2]. The combination of chloroquine with zinc enhanced chloroquine's cytotoxicity and induced apoptosis in A2780 cells[3]. Chloroquine (0.01-100μM; 48?hours) potently blocked virus infection (vero E6 cells infected with SARS-CoV-2) at low-micromolar concentration (EC50=1.13?μM). Chloroquine blocks virus infection by increasing endosomal pH required for virus/cell fusion, as well as interfering with the glycosylation of cellular receptors of SARS-CoV[4]. |
| Concentration | Treated Time | Description | References | |
| Werner syndrome-specific mesenchymal stem cells (WS hMSCs) | 0.2 μM to 100 μM | Low concentrations of CQ (0.2-5 μM) promoted cell self-renewal, while higher concentrations (20 μM or above) inhibited cell proliferation. Treatment with 1 μM CQ decreased the percentage of SA-β-gal-positive cells and increased the number of Ki67-positive cells, while also reducing IL-6 secretion. | Protein Cell. 2022 Jun;13(6):454-461. | |
| U2OS cells expressing GFP-TFEB fusion protein | 0.1, 0.3, 1, 3, 10, 30 μM | 6 h | Triggered TFEB nuclear translocation | Cell Death Dis. 2021 Jan 6;12(1):6. |
| Human glioma H4 cells | 10, 20, 40 μM | 6 h | Induced GFP-LC3 dot formation, indicating autophagosome accumulation | Cell Death Dis. 2021 Jan 6;12(1):6. |
| Human U2OS osteosarcoma cells | 10, 20, 40 μM | 6 h | Induced GFP-LC3 dot formation, indicating autophagosome accumulation | Cell Death Dis. 2021 Jan 6;12(1):6. |
| A549 | 71.3 ± 6.1 μM | Induced apoptosis, suppressed autophagy | Int J Nanomedicine. 2024 Jul 5;19:6777-6809. | |
| H460 | 55.6 ± 12.5 μM | Induced apoptosis, suppressed autophagy | Int J Nanomedicine. 2024 Jul 5;19:6777-6809. | |
| H1299 | 50 μM | Inhibited autophagy, decreased transcriptional activity and disrupted the localization of p53-R273H | Int J Nanomedicine. 2024 Jul 5;19:6777-6809. | |
| A549 | 2.5 ~ 60 μM | Blocked the PI3K/AKT signaling pathway, mediated mitochondrial apoptosis and inhibited autophagy | Int J Nanomedicine. 2024 Jul 5;19:6777-6809. | |
| MCF-7 | 20 μM | Inhibition of autophagy/mitophagy, induced apoptosis | Int J Nanomedicine. 2024 Jul 5;19:6777-6809. | |
| BT549 | 20 μM | Inhibition of autophagy/mitophagy, induced apoptosis | Int J Nanomedicine. 2024 Jul 5;19:6777-6809. | |
| MDA-MB-231 | 20 μM | Inhibition of autophagy/mitophagy, induced apoptosis | Int J Nanomedicine. 2024 Jul 5;19:6777-6809. | |
| MiaPaca-2 | 100 μM | 72 h | Assess the cytotoxicity of CQ-HES, results showed similar cytotoxicity between CQ-HES and HCQ | Biomacromolecules. 2017 Aug 14;18(8):2247-2257. |
| MiaPaca-1 | 100 μM | 72 h | Assess the cytotoxicity of CQ-HES, results showed similar cytotoxicity between CQ-HES and HCQ | Biomacromolecules. 2017 Aug 14;18(8):2247-2257. |
| AsPC-1 | 100 μM | 72 h | Assess the cytotoxicity of CQ-HES, results showed similar cytotoxicity between CQ-HES and HCQ | Biomacromolecules. 2017 Aug 14;18(8):2247-2257. |
| Calu-3 cells | 64.7 μM (CQ), 119 μM (HCQ) | To study the inhibitory effect of CQ and HCQ on SARS-CoV-2 infection, results showed that the effective dose in Calu-3 cells was significantly higher than in Vero E6 cells. | J Mol Cell Biol. 2021 Jul 6;13(3):175-184. | |
| Vero E6 cells | 6.5 μM | To study the inhibitory effect of CQ and HCQ on SARS-CoV-2 infection, results showed that CQ and HCQ effectively inhibited viral invasion in Vero E6 cells. | J Mol Cell Biol. 2021 Jul 6;13(3):175-184. | |
| Administration | Dosage | Frequency | Description | References | ||
| Mice | HCT116 human colon carcinoma xenografts | Intraperitoneal injection | 20 mg/kg | Every second day for 16 days | Evaluate the inhibitory effect of CQ on tumor growth, results showed CQ as a single-agent treatment had no significant effect on tumor growth | Autophagy. 2014 Apr;10(4):562-71 |
| C57BL/6J mice | Nilotinib-induced nephrotoxicity model | Intragastric administration | 30 mg/kg | Daily for 30 days | To investigate the intervention effect of chloroquine on nilotinib-induced nephrotoxicity. The results showed that chloroquine significantly ameliorated nilotinib-induced renal injury, reduced blood urea nitrogen and serum creatinine levels, and decreased renal fibrosis. | Adv Sci (Weinh). 2023 Sep;10(26):e2302002. |
| Sprague Dawley (SD) rats | 24-month-old rats | Oral | 0.1 mg/kg | Twice a week for 5 months | Low-dose CQ treatment extended the lifespan of rats, repressed systemic inflammation, and inhibited fibrosis across multiple tissues. CQ treatment also reduced serum TNF-α levels and the numbers of circulating white blood cells and neutrophils, indicating attenuated chronic inflammation. | Protein Cell. 2022 Jun;13(6):454-461. |
| Mice | C57Bl/6j mice | Intraperitoneal injection | 50 mg/kg | Once daily for 10 days | Detected eIF2α phosphorylation levels, indicating that HCQ can induce eIF2α phosphorylation in vivo | Cell Death Dis. 2021 Jan 6;12(1):6. |
| Mouse | Breast cancer model | Intraperitoneal injection | 40 mg/kg | Once every two days | Inhibition of autophagy/mitophagy, induced apoptosis | Int J Nanomedicine. 2024 Jul 5;19:6777-6809. |
| Mice | HCoV-OC43 infection model | 15 mg/kg | To study the preventive effect of CQ on HCoV-OC43 infection, results showed that 15 mg/kg of CQ effectively prevented infection in mice. | J Mol Cell Biol. 2021 Jul 6;13(3):175-184. |
| 計算器 | ||||
| 存儲液制備 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
3.13mL 0.63mL 0.31mL |
15.63mL 3.13mL 1.56mL |
31.26mL 6.25mL 3.13mL |
|
| CAS號 | 54-05-7 |
| 分子式 | C18H26ClN3 |
| 分子量 | 319.87 |
| SMILES Code | CC(NC1=CC=NC2=CC(Cl)=CC=C12)CCCN(CC)CC |
| MDL No. | MFCD00024009 |
| 別名 | NSC-187208; CHQ; CQ |
| 英文名稱 | N4-(7-Chloroquinolin-4-yl)-N1,N1-diethylpentane-1,4-diamine |
| 運輸 | 藍冰 |
| InChI Key | WHTVZRBIWZFKQO-UHFFFAOYSA-N |
| Pubchem ID | 2719 |
| 存儲條件 |
In solvent -20°C: 3-6個月 -80°C: 12個月 Pure form Keep in dark place, sealed in dry, 2-8°C |
| 溶解方案 |
DMSO 中的溶解度 : 200 mg/mL (625.25 mM; 超聲助溶; 吸濕的 DMSO 對產品的溶解度有顯著影響,請使用新開封的 DMSO) Ethanol 中的溶解度 : 100 mg/mL (312.63 mM; 超聲助溶) 以下溶解方案都請先按照體外實驗的方式配制澄清的儲備液,再依次添加助溶劑: ——為保證實驗結果的可靠性,澄清的儲備液可以根據儲存條件,適當保存;體內實驗的工作液,建議現用現配,當天使用; 以下溶劑前顯示的百分比是指該溶劑在終溶液中的體積占比;如在配制過程中出現沉淀、析出現象,可以通過加熱和/或超聲的方式助溶
|
滬公網安備 31011002007707號
滬ICP備2025150922號-1
危化品經營許可證:滬(楊)應急管危經許[2025]204822(QY)